Treatments that are highly selective in inhibiting the body's immune response have the potential to increase quality of life for people with plaque psoriasis.
Plaque Psoriasis is an autoimmune condition characterised by dry, itchy and scaly skin patches (plaques).
The investigational drug for this study is TAK-279 and is given as an oral tablet. TAK-279 is a highly selective in inhibiting the body’s immune response, and has been well tolerated in previous clinical trials.
The purpose of this research project is to measure how safe and effective this medication is in treating participants with plaque psoriasis. The outcome of this project could support new treatments to increase quality of life in people with plaque psoriasis.
Who can take part
You may be able to participate in this study if you:
- Are at least 18 years of age with diagnosis of chronic plaque psoriasis
- Have at least 10% of your body surface area affected by psoriasis
You may not be able to participate if you:
- Have a diagnosis of non-plaque psoriasis - for example, erythrodermic, pustular, guttate
- Have a history of excessive sun exposure - for example, tanning booths
- Are unable to comply with having no biologics medications for 6 months or systemic medications for 4 weeks or topical medications for 2 weeks
What's involved
You will need to:
- Attend the Royal Melbourne Hospital approximately 17 times over the 12-month trial period with most study visits taking about one hour. Note that your first and second visit will be longer.
- Undertake a medical history, physical examination, height and weight
- Provide blood and urine samples
Ethics
All research in Australia involving human participants is reviewed by an independent group called a Human Research Ethics Committee (HREC). The ethical aspects of this research study have been approved by the Royal Melbourne Hospital HREC.
This study is being carried out according to the National Statement on Ethical Conduct in Human Research (2007). This statement protects the interests of people who agree to participate in human research studies.